Reported about 9 hours ago
Merck, the American drugmaker, has announced a $1 billion investment in a new plant in Delaware to expand domestic production in response to President Trump's tariffs. This facility will manufacture biologic drugs and Keytruda, Merck's leading cancer treatment, marking the company's first U.S.-based production site for this drug. The new plant is expected to create over 500 permanent jobs and around 4,000 construction roles, with operations beginning by 2028 and production of experimental drugs by 2030.
Source: YAHOO